Psoriatic Arthritis

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.

AUSTIN, Texas — Communication and awareness of the myriad disease domains are essential to preventing a misdiagnosis of psoriatic arthritis, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.

Brepocitinib, in doses of either 30 mg or 60 mg, is superior to placebo in reducing signs and symptoms of psoriatic arthritis and is “generally well tolerated” through 52 weeks, according to data published in Arthritis & Rheumatology.

Patients with autoimmune diseases or long COVID who used a personalized digital care program alongside other non-pharmacologic strategies were more likely to achieve better health-related quality of life scores, according to data.

Secukinumab and adalimumab demonstrate similar efficacy regarding the resolution of enthesitis over 52 weeks in patients with psoriatic arthritis, according to data published in Rheumatology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

M. Elaine Husni, MD, MPH, spoke with Healio about treatment and management options in psoriatic arthritis, including lifestyle changes. “We now have really embraced the concept of wellness strategies,” said Husni, vice chair of rheumatology and director of the Arthritis and Musculoskeletal Center and staff physician in the Orthopedic and Rheumatologic Institute at Cleveland Clinic, and assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.